All-trans retinoic acid and arsenic combination therapy benefits low-to-intermediate-risk patients with newly diagnosed acute promyelocytic leukaemia: a long-term follow-up based on multivariate analysis

Br J Haematol. 2015 Oct;171(2):277-280. doi: 10.1111/bjh.13375. Epub 2015 Mar 30.
No abstract available

Keywords: acute promyelocytic leukaemia; all-trans retinoic acid; arsenic; long-term survival; risk factors.

Publication types

  • Letter